|
ZA782648B
(en)
*
|
1977-05-23 |
1979-06-27 |
Ici Australia Ltd |
The prevention,control or eradication of infestations of ixodid ticks
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
|
ES2108120T3
(es)
|
1991-05-10 |
1997-12-16 |
Rhone Poulenc Rorer Int |
Compuestos bis arilicos y heteroarilicos mono- y biciclicos que inhiben tirosina quinasa receptora de egf y/o pdgf.
|
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
|
AU661533B2
(en)
|
1992-01-20 |
1995-07-27 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
|
US5262564A
(en)
|
1992-10-30 |
1993-11-16 |
Octamer, Inc. |
Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
|
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
|
DE69334100T2
(de)
|
1992-11-13 |
2007-07-19 |
Immunex Corp., Seattle |
Elk ligand, ein cytokin
|
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
|
JPH08503971A
(ja)
|
1993-10-01 |
1996-04-30 |
チバ−ガイギー アクチェンゲゼルシャフト |
ピリミジンアミン誘導体及びその調製のための方法
|
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
|
WO1995014023A1
(en)
|
1993-11-19 |
1995-05-26 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
|
SK78196A3
(en)
|
1993-12-17 |
1997-02-05 |
Sandoz Ag |
Rapamycin demethoxy-derivatives, preparation method thereof and pharmaceutical agent containing them
|
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
|
CA2189028A1
(en)
|
1994-04-15 |
1995-10-26 |
Gary M. Fox |
Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
|
|
ES2109796T3
(es)
|
1994-05-03 |
1998-01-16 |
Ciba Geigy Ag |
Derivados de pirrolopirimidilo con efecto antiproliferante.
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
JP3088018B2
(ja)
|
1995-03-30 |
2000-09-18 |
ファイザー・インコーポレーテッド |
キナゾリン誘導体
|
|
DE69609602T2
(de)
|
1995-04-03 |
2001-04-12 |
Novartis Ag |
Pyrazolderivate und verfahren zu deren herstellung
|
|
ATE198326T1
(de)
|
1995-04-20 |
2001-01-15 |
Pfizer |
Arylsulfonamido-substituierte hydroxamsäure derivate als inhibitoren von mmp und tnf
|
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
|
CA2219659C
(en)
|
1995-06-09 |
2008-03-18 |
Novartis Ag |
Rapamycin derivatives
|
|
CZ1598A3
(cs)
|
1995-07-06 |
1998-04-15 |
Novartis Ag |
Pyrrolopyrimidiny a způsoby jejich přípravy
|
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
|
ATE225343T1
(de)
|
1995-12-20 |
2002-10-15 |
Hoffmann La Roche |
Matrix-metalloprotease inhibitoren
|
|
ATE217873T1
(de)
|
1996-01-23 |
2002-06-15 |
Novartis Erfind Verwalt Gmbh |
Pyrrolopyrimidinen und verfahren zu deren herstellung
|
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
|
CA2249739A1
(en)
|
1996-03-15 |
1997-09-25 |
Novartis Ag |
Novel n-7-heterocyclyl pyrrolo[2,3-d]pyridines and their use
|
|
CN100503580C
(zh)
|
1996-04-12 |
2009-06-24 |
沃尼尔·朗伯公司 |
酪氨酸激酶的不可逆抑制剂
|
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
|
CA2258548C
(en)
|
1996-06-24 |
2005-07-26 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
|
EP0937082A2
(en)
|
1996-07-12 |
1999-08-25 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
|
DK0912559T3
(da)
|
1996-07-13 |
2003-03-10 |
Glaxo Group Ltd |
Kondenserede heterocykliske forbindelser som proteintyrosinkinaseinhibitorer
|
|
TR199900048T2
(xx)
|
1996-07-13 |
1999-04-21 |
Glaxo Group Limited |
Protein tirozin kinaz inhibit�rleri olarak bisiklik heteroaromatik bile�ikler
|
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
|
CZ11899A3
(cs)
|
1996-07-18 |
1999-11-17 |
Pfizer Inc. |
Fosfinátové sloučeniny, farmaceutické prostředky, způsob inhibice matričních metalloproteinas nebo produkce faktoru nekrosy nádorů a způsob léčení
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
CA2263129C
(en)
|
1996-08-16 |
2007-01-09 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
WO1998007726A1
(en)
|
1996-08-23 |
1998-02-26 |
Novartis Ag |
Substituted pyrrolopyrimidines and processes for their preparation
|
|
SK21499A3
(en)
|
1996-08-23 |
2000-05-16 |
Pfizer |
Arylsulfonylamino hydroxamic acid derivatives
|
|
WO1998014449A1
(en)
|
1996-10-02 |
1998-04-09 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
|
AU720135B2
(en)
|
1996-10-02 |
2000-05-25 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
|
WO1998030566A1
(en)
|
1997-01-06 |
1998-07-16 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
|
US6303636B1
(en)
|
1997-02-03 |
2001-10-16 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
|
WO1998033798A2
(en)
|
1997-02-05 |
1998-08-06 |
Warner Lambert Company |
Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
|
|
AU5493598A
(en)
|
1997-02-07 |
1998-08-26 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
|
CA2280151C
(en)
|
1997-02-11 |
2005-12-13 |
Pfizer Inc. |
Arylsulfonyl hydroxamic acid derivatives
|
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
|
AU8689298A
(en)
|
1997-08-05 |
1999-03-01 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
|
SK1362000A3
(en)
|
1997-08-08 |
2000-10-09 |
Pfizer Prod Inc |
Aryloxyarylsulfonylamino hydroxamic acid derivatives
|
|
WO2000012089A1
(en)
|
1998-08-31 |
2000-03-09 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
|
US6509173B1
(en)
|
1997-10-21 |
2003-01-21 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
|
|
BR9814018A
(pt)
*
|
1997-11-11 |
2000-09-26 |
Pfizer Prod Inc |
Derivados de tienopirimidina e tienopiridina úteis como agentes anticâncer
|
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
|
GB9800569D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
|
IL137409A0
(en)
|
1998-02-09 |
2001-07-24 |
Genentech Inc |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
ATE430149T1
(de)
|
1998-03-04 |
2009-05-15 |
Bristol Myers Squibb Co |
Heterocyclen substituierte imidazopyrazine als protein- tyrosin-kinase-inhibitoren
|
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
|
WO1999061422A1
(en)
|
1998-05-29 |
1999-12-02 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
|
UA60365C2
(ru)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего
|
|
JP2002520324A
(ja)
|
1998-07-10 |
2002-07-09 |
メルク エンド カムパニー インコーポレーテッド |
新規な血管形成インヒビター
|
|
EP1004578B1
(en)
|
1998-11-05 |
2004-02-25 |
Pfizer Products Inc. |
5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
|
|
EP1165085B1
(en)
|
1999-03-30 |
2006-06-14 |
Novartis AG |
Phthalazine derivatives for treating inflammatory diseases
|
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
|
DK1187918T4
(da)
|
1999-06-07 |
2009-02-23 |
Immunex Corp |
TEK-antagonister
|
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
|
CA2378179A1
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
|
ES2219388T3
(es)
|
1999-08-24 |
2004-12-01 |
Ariad Gene Therapeutics, Inc. |
28-epi-rapalogos.
|
|
AU769222B2
(en)
|
1999-11-05 |
2004-01-22 |
Genzyme Corporation |
Quinazoline derivatives as VEGF inhibitors
|
|
PT1233943E
(pt)
|
1999-11-24 |
2011-09-01 |
Sugen Inc |
Formulações para agentes farmacêuticos ionizáveis como ácidos livres ou bases livres
|
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
ATE373078T1
(de)
|
2000-02-24 |
2007-09-15 |
Xcyte Therapies Inc |
Gleichzeitige stimulation und konzentration von zellen
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
JP2003523768A
(ja)
|
2000-02-25 |
2003-08-12 |
イミュネックス・コーポレーション |
インテグリンアンタゴニスト
|
|
JP2002105081A
(ja)
*
|
2000-07-28 |
2002-04-10 |
Nikken Chem Co Ltd |
新規チオフェンニ環化合物
|
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
|
CA2423981A1
(en)
*
|
2000-09-29 |
2003-03-28 |
Kimiko Ichikawa |
Thienopyrimidine compounds and salts thereof and process for the preparation of the same
|
|
ES2556946T3
(es)
|
2000-12-21 |
2016-01-21 |
Novartis Ag |
Pirimidinaminas como moduladores de la angiogénesis
|
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
|
AU2002364211A1
(en)
*
|
2001-12-21 |
2003-07-15 |
Bayer Pharmaceuticals Corporation |
Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
|
BRPI0410785A
(pt)
|
2003-05-23 |
2006-06-20 |
Wyeth Corp |
molécula de ácido nucleico isolada, célula hospedeira, animal transgênico não humano, proteìna isolada, oligonucleotìdeo anti-sentido, molécula de sirna, anticorpo isolado, métodos de triagem quanto aos compostos de teste capazes de inibir, de intensificar ou imitar a interação do gitrl com o gitr, para diagnosticar doenças, para tratar um paciente em risco ou diagnosticado com uma doença, para induzir e para inibir a proliferação de uma população celular contendo células t efetoras, de bloquear a supressão e de supressão de uma população celular que inclua células t efetoras na presença de células t reguladoras cd4+cd25+, e para tratar uma doença, composição farmacêutica, e, adjuvante de vacina
|
|
PT1646634E
(pt)
|
2003-07-08 |
2009-02-16 |
Novartis Ag |
Utilização de rapamicina e derivados de rapamicina para o tratamento de perda óssea
|
|
WO2005016252A2
(en)
|
2003-07-11 |
2005-02-24 |
Ariad Gene Therapeutics, Inc. |
Phosphorus-containing macrocycles
|
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
|
TW200523262A
(en)
|
2003-07-29 |
2005-07-16 |
Smithkline Beecham Corp |
Inhibitors of AKT activity
|
|
GB0320300D0
(en)
*
|
2003-08-29 |
2003-10-01 |
Cancer Rec Tech Ltd |
Pyrimidothiophene compounds
|
|
EP1692318A4
(en)
|
2003-12-02 |
2008-04-02 |
Genzyme Corp |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LUNG CANCER
|
|
US20080058431A1
(en)
|
2004-03-26 |
2008-03-06 |
Gen-Sheng Feng |
Modulators of Shp2 Tyrosine Phosphatase and Their Use in the Treatment of Body Weight Disorders
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
EP1765402A2
(en)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
UA87153C2
(ru)
|
2004-08-26 |
2009-06-25 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения как ингибиторы протеинкиназы
|
|
TW200626610A
(en)
|
2004-10-13 |
2006-08-01 |
Wyeth Corp |
Analogs of 17-hydroxywortmannin as PI3K inhibitors
|
|
KR20140008471A
(ko)
*
|
2004-10-21 |
2014-01-21 |
다우 아그로사이언시즈 엘엘씨 |
살진균 활성을 갖는 티에노-피리미딘 화합물
|
|
PT1866339E
(pt)
|
2005-03-25 |
2013-09-03 |
Gitr Inc |
Moléculas de ligação a gitr e suas utilizações
|
|
EP2418278A3
(en)
|
2005-05-09 |
2012-07-04 |
Ono Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
WO2007034327A1
(en)
|
2005-09-20 |
2007-03-29 |
Pfizer Products Inc. |
Dosage forms and methods of treatment using a tyrosine kinase inhibitor
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
WO2007117699A2
(en)
|
2006-04-07 |
2007-10-18 |
University Of South Florida |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs
|
|
EP2114949A1
(en)
|
2006-12-07 |
2009-11-11 |
F.Hoffmann-La Roche Ag |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
|
WO2008124815A1
(en)
|
2007-04-10 |
2008-10-16 |
University Of South Florida |
Method of activating nk cells
|
|
CA2693677C
(en)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
|
PE20090678A1
(es)
|
2007-09-12 |
2009-06-27 |
Genentech Inc |
Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
|
|
WO2009049098A2
(en)
|
2007-10-09 |
2009-04-16 |
Indiana University Research & Technology Corporation |
Materials and methods for regulating the activity of phosphatases
|
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック， インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
|
WO2009135000A2
(en)
|
2008-04-30 |
2009-11-05 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs
|
|
CA2729810A1
(en)
|
2008-07-02 |
2010-01-07 |
Emergent Product Development Seattle, Llc |
Tgf-.beta. antagonist multi-target binding proteins
|
|
WO2010011666A2
(en)
|
2008-07-21 |
2010-01-28 |
University Of South Florida |
Indoline scaffold shp-2 inhibitors and cancer treatment method
|
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性ｇｉｔｒリガンド発現細胞
|
|
WO2010054285A2
(en)
*
|
2008-11-10 |
2010-05-14 |
National Health Research Institutes |
Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
|
|
WO2010121212A2
(en)
|
2009-04-17 |
2010-10-21 |
H. Lee Moffit Cancer Center And Research Institute, Inc. |
Indoline scaffold shp-2 inhibitors and method of treating cancer
|
|
US9567318B2
(en)
|
2009-08-17 |
2017-02-14 |
Memorial Sloan-Kettering Cancer Center |
Substituted pyrimidine compounds and uses thereof
|
|
AU2010289677B2
(en)
|
2009-09-03 |
2014-07-31 |
Merck Sharp & Dohme Llc |
Anti-GITR antibodies
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
WO2011090762A1
(en)
|
2009-12-29 |
2011-07-28 |
Emergent Product Development Seattle, Llc |
Heterodimer binding proteins and uses thereof
|
|
US8637684B2
(en)
|
2010-05-12 |
2014-01-28 |
Wisconsin Alumni Research Foundation |
Tautomycetin and tautomycetin analog biosynthesis
|
|
WO2012041524A1
(en)
|
2010-10-01 |
2012-04-05 |
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) |
Hydrazonopyrazolones as protein tyrosine phosphatase inhibitors
|
|
EP2655374B1
(en)
*
|
2010-12-20 |
2019-10-23 |
Incyte Holdings Corporation |
N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
|
|
PT2937349T
(pt)
|
2011-03-23 |
2017-03-24 |
Amgen Inc |
Inibidores duais tricíclicos fusionados de cdk 4/6 e flt3
|
|
US20130108641A1
(en)
|
2011-09-14 |
2013-05-02 |
Sanofi |
Anti-gitr antibodies
|
|
WO2014113584A1
(en)
|
2013-01-16 |
2014-07-24 |
Rhode Island Hospital |
Compositions and methods for the prevention and treatment of osteolysis and osteoporosis
|
|
AU2014235474B2
(en)
|
2013-03-15 |
2017-05-25 |
Novartis Ag |
Antibody drug conjugates
|
|
EP2988741B1
(en)
|
2013-04-26 |
2019-11-27 |
Indiana University Research&Technology Corporation |
Hydroxyindole carboxylic acid based inhibitors for oncogenic src homology-2 domain containing protein tyrosine phosphatase-2 (shp2)
|
|
WO2015000959A1
(en)
*
|
2013-07-03 |
2015-01-08 |
Norwegian University Of Science And Technology (Ntnu) |
4-amino-6-aryl[2,3-d]pyrimidines for the inhibition of egfr tyrosine kinase
|
|
EP3016652A4
(en)
|
2013-07-03 |
2017-03-08 |
Indiana University Research and Technology Corporation |
Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors
|
|
EP2826586A1
(en)
|
2013-07-18 |
2015-01-21 |
Siemens Aktiengesellschaft |
A method and a system for machining an object
|
|
JP6523303B2
(ja)
|
2014-01-17 |
2019-05-29 |
ノバルティス アーゲー |
Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物
|
|
CN105899493B
(zh)
|
2014-01-17 |
2019-03-29 |
诺华股份有限公司 |
用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物
|
|
CN105418632B
(zh)
*
|
2014-09-19 |
2020-02-21 |
上海创诺医药集团有限公司 |
噻吩并嘧啶类衍生物、其制备方法及其在医药上的应用
|
|
WO2016077793A1
(en)
|
2014-11-14 |
2016-05-19 |
Children's Hospital Medical Center |
Sos1 inhibitors for cancer treatment
|
|
TW202204345A
(zh)
*
|
2015-01-16 |
2022-02-01 |
美商通用醫院公司 |
改善mRNA剪接之化合物
|
|
US20180121597A1
(en)
|
2015-05-22 |
2018-05-03 |
Allosta Pharmaceuticals |
Methods to Prepare and Employ Binding Site Models for Modulation of Phosphatase Activity and Selectivity Determination
|
|
US10532977B2
(en)
|
2015-06-01 |
2020-01-14 |
Indiana University Research And Technology Corporation |
Small molecule inhibitors of protein tyrosine phosphatases and uses thereof
|
|
CN107922388B
(zh)
|
2015-06-19 |
2020-12-29 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
US10975080B2
(en)
|
2015-06-19 |
2021-04-13 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of SHP2
|
|
WO2017078499A2
(ko)
|
2015-11-06 |
2017-05-11 |
경북대학교 산학협력단 |
단백질 타이로신 탈인산화효소 억제제를 포함하는 신경염증성 질환의 예방 또는 치료용 조성물
|
|
WO2017079723A1
(en)
|
2015-11-07 |
2017-05-11 |
Board Of Regents, The University Of Texas System |
Targeting proteins for degradation
|
|
WO2017100279A1
(en)
|
2015-12-09 |
2017-06-15 |
West Virginia University |
Chemical compound for inhibition of shp2 function and for use as an anti-cancer agent
|
|
WO2017156397A1
(en)
|
2016-03-11 |
2017-09-14 |
Board Of Regents, The University Of Texas Sysytem |
Heterocyclic inhibitors of ptpn11
|
|
CN109071567B
(zh)
*
|
2016-05-19 |
2021-03-23 |
四川大学 |
抗流感小分子化合物及其制备方法和用途
|
|
WO2017210134A1
(en)
|
2016-05-31 |
2017-12-07 |
Board Of Regents, University Of Texas System |
Heterocyclic inhibitors of ptpn11
|
|
CN109311848B
(zh)
|
2016-06-07 |
2022-02-01 |
北京加科思新药研发有限公司 |
可用作shp2抑制剂的新型杂环衍生物
|
|
EP4302834A2
(en)
|
2016-07-12 |
2024-01-10 |
Revolution Medicines, Inc. |
2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
|
|
CN110167928A
(zh)
*
|
2016-12-22 |
2019-08-23 |
勃林格殷格翰国际有限公司 |
作为sos1抑制剂的新型经苄基氨基取代的喹唑啉和衍生物
|
|
WO2018129402A1
(en)
|
2017-01-06 |
2018-07-12 |
Oregon Health & Science University |
Compositions and methods used in diagnosing and treating colorectal cancer
|
|
CN110730678B
(zh)
|
2017-01-10 |
2022-07-15 |
诺华股份有限公司 |
包含alk抑制剂和shp2抑制剂的药物组合
|
|
GB201700814D0
(en)
*
|
2017-01-17 |
2017-03-01 |
Liverpool School Tropical Medicine |
Compounds
|
|
BR112019014527A2
(pt)
|
2017-01-23 |
2020-02-27 |
Revolution Medicines, Inc. |
Compostos de piridina como inibidores de shp2 alostéricos
|
|
WO2018136265A1
(en)
|
2017-01-23 |
2018-07-26 |
Revolution Medicines, Inc. |
Bicyclic compounds as allosteric shp2 inhibitors
|
|
EP3589647A1
(en)
|
2017-02-28 |
2020-01-08 |
Novartis AG |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
EP3601267A1
(en)
*
|
2017-03-21 |
2020-02-05 |
Bayer Pharma Aktiengesellschaft |
2-methyl-quinazolines
|
|
US10988466B2
(en)
|
2017-03-23 |
2021-04-27 |
Jacobio Pharmaceuticals Co., Ltd. |
Heterocyclic derivatives useful as SHP2 inhibitors
|
|
EP3619216A1
(en)
|
2017-05-02 |
2020-03-11 |
Revolution Medicines, Inc. |
Rapamycin analogs as mtor inhibitors
|
|
MX2020002608A
(es)
|
2017-09-07 |
2020-09-18 |
Revolution Medicines Inc |
Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cáncer.
|
|
WO2019051469A1
(en)
|
2017-09-11 |
2019-03-14 |
Krouzon Pharmaceuticals, Inc. |
SHP2 OCTAHYDROCYCLOPENTA [C] PYRROLE ALLOSTERIC INHIBITORS
|
|
TW202014208A
(zh)
|
2018-05-01 |
2020-04-16 |
美商銳新醫藥公司 |
作為ｍＴＯＲ抑制劑之Ｃ４０-、Ｃ２８-及Ｃ-３２連接之雷帕黴素類似物
|
|
IL278335B1
(en)
|
2018-05-01 |
2024-05-01 |
Revolution Medicines Inc |
C26-linked rapamycin analogs as MTOR inhibitors
|